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Herpes gestationis (HG), also known as pemphigoid
gestationis or gestational pemphigoid, was first identi-
fied in 1872 by John Laws Milton, and is the most
clearly characterized dermatosis of pregnancy. HG is a
rare autoimmune bullous disease of pregnancy and the
puerperium. It has been rarely associated with choriocar-
cinoma and molar pregnancy. The term herpes is used
because of the frequent presence of grouped or her-
petiform lesions. HG has an estimated incidence of 
1 in 50,000 pregnancies worldwide [1]. HG shows 
a strong genetic linkage to HLA-DR3 and DR4 [2,3].
Some studies have shown that 61–80% of HG patients
express DR3, 52–53% express DR4, and 43–50% express
both MHC II genes. It usually affects multiparous women
in late pregnancy, but it may begin early in pregnancy
or within a few weeks postpartum. Common sites of
involvement are the abdomen and the extremities. It is
caused by the development of IgG1 antibodies to the
basement membrane protein BP-180 [4–6].
A 26-year-old primigravida was admitted from the
emergency department with 38 weeks’ amenorrhea, and
a 1-month history of pruritic vesiculobullous lesions all
over her body, including her back and feet, and bilat-
eral foot edema. She also complained of decreased
fetal movements over the previous 3 days and fever
since the previous day. The patient had been taking
oral steroids (prednisolone; Wysolone; Wyeth Ltd.,
Mumbai, India; 40 mg once a day) for the past month
and chlorpheniramine maleate tablets for 10 days, as
well as using Condy’s compresses and framycetin sulfate
1% cream (Soframycin; Aventis Pharma Ltd., Mumbai,
India) locally on the vesicular lesions for the past
month, as prescribed by her physician. However, the
patient had experienced only minimal relief.
The patient was febrile, with a pulse rate of 110
beats/min and a blood pressure of 130/80mmHg. There
were vesiculobullous lesions all over her body, including
her abdomen, back, limbs and breast. She also had bilat-
eral foot edema (Figure). Her oral mucosa was normal.
Abdominal examination revealed a uterine height cor-
responding to 34 weeks’ gestation with cephalic pres-
entation, decreased liquor, and a regular fetal heart
rate of 142 beats/min. Speculum examination revealed
a healthy cervix and vagina. No lesions were seen on
the vaginal mucosa. Ultrasonography showed a single
live fetus corresponding to 36 weeks’ maturity with
mild intrauterine growth retardation. The results of a
nonstress test were negative. Her hemoglobin was
10.2 g/dL. Tests for syphilis and human immunodefi-
ciency virus were negative.
Based on the findings of intrauterine growth retarda-
tion, decreased fetal movements and negative nonstress
test, the patient underwent emergency lower segment
cesarean section under general anesthesia. A 2.35-kg
baby boy was born with a normal Apgar score and no
evidence of skin lesions.
New, less severe lesions appeared on the patient’s
body and older lesions started crusting from the 
third day of puerperium. The baby had no such lesions
and was fully immunized. The patient did not breast-
feed the baby because of the lesions on her breast,
even though there were no other contraindications for
breastfeeding. The baby was fed cow’s milk. The patient
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Figure. Clinical photograph showing lesions over the
abdomen and lower limbs.
remained in hospital for 10 days. Steroids were contin-
ued during the puerperium and were slowly tapered
after 6 weeks.
HG is an autoimmune disease and may be associ-
ated with other autoimmune diseases, such as Graves
disease, vitiligo and alopecia areata. It is a disease
unique to pregnancy, which usually starts with pruritic
papular and urticarial eruptions on the abdomen, and
then spread to other flexural areas of skin. Generalized
bullous eruptions rapidly ensue, which may affect the
palms and soles. Facial and mucosal involvement, as
was seen in our patient, is rare. HG is generally seen in
the second or third trimesters of pregnancy, although
the disease has been reported as early as during the
first 2 weeks of gestation in rare cases. In our patient,
lesions first appeared in the third trimester. In most
instances, HG patients are effectively treated during the
early stages of the disease, and the pregnancy usually
ends with normal labor. Most patients improve follow-
ing delivery, and the skin eruptions gradually disap-
pear. Several authors have documented recurrences of
the disease in subsequent pregnancies [7,8], and inter-
estingly, the disease may increase in severity with each
pregnancy. An uninvolved or skipped pregnancy following
a previously affected pregnancy is seen in approximately
8% of HG patients [9]. Recurrences associated with
menses or ovulation, or with the subsequent use of oral
contraceptives, have also been reported. HG is not
associated with maternal risks other than an increased
risk of Graves disease, although there have been reports
of miscarriages and an increased frequency of prema-
ture deliveries with low birth weight newborns [10].
On rare occasions (1 in 100,000 pregnancies), similar
lesions can develop in neonates, but these are tran-
sient and gradually disappear during first 2 or 3 days of
life without any treatment [11,12]. Infants of mothers
treated with oral steroids should be monitored for 
evidence of adrenal insufficiency. No increase in fetal
morbidity or mortality has been documented, except
for one case of fetal cerebral hemorrhage.
The histologic features of HG are characterized by the
detachment of the epidermis from the dermis and by an
intense inflammatory infiltrate rich in eosinophils and
neutrophils in the upper dermis. HG appears to be medi-
ated by autoantibodies specific for the hemidesmoso-
mal glycoprotein BP-180. Provost and Tomasi [13]
reported that HG was characterized by linear deposi-
tion of complement C3 along the cutaneous basement
membrane zone (BMZ) of perilesional skin, demon-
strated by direct immunofluorescence. They also
reported that the serum of these patients contained
“HG factor” (a complement-fixing anti-BMZ IgG1 anti-
body, identified by indirect immunofluorescence test).
Demonstration of C3 deposition along the BMZ by
direct immunofluorescence is accepted as the gold stan-
dard for the diagnosis of HG.
HG should be differentiated from other dermatoses
of pregnancy, especially pruritic urticarial papules and
plaques of pregnancy, allergic contact dermatitis, and
drug eruptions. A careful history and clinical examina-
tion are usually sufficient to rule out allergic contact
drug eruptions and preexisting bullous disease with flare
during pregnancy. Accurate differentiation between HG
and pruritic urticarial papules and plaques of pregnancy
has important implications for fetal and maternal
prognosis. Immunofluorescence studies are the best
way of making this differentiation.
The first-line treatment of HG, especially in advanced
lesions, is systemic corticosteroids at a dose of
0.5 mg/kg/day of prednisolone. The daily dose should
not exceed 80 mg, except in rare circumstances when
the condition is severe, where 180 mg/day has been
used. Some authors have suggested increasing the
steroid dose for a short time during the early postpartum
period to prevent exacerbations. Early urticarial lesions
may respond to topical corticosteroids, as well as to
oral antihistamines. Alternative medications are dapsone,
sulfapyridine, pyridoxine, and cyclosporine. Refractory
cases of HG respond better to adjuvant medications,
such as methotrexate, azathioprine, gold, pyridoxine
and cyclosporine, especially in the postpartum period.
However, their use is limited to patients who are not
breastfeeding. Early delivery may be warranted in refrac-
tory cases. One report also indicated some benefit from
minocycline in a case of postpartum HG [14].
Plasmapheresis or chemical oophorectomy with
goserelin has also been used for recalcitrant HG with
some success. Plasmapheresis should be considered 
in patients who fail to respond to high doses of oral
steroids, or when oral steroids are contraindicated [15].
High-dose intravenous immune globulin combined
with cyclosporine has been used to treat HG with
some success [16]. Based on the possibility that
autoantibodies and T cells from HG against BP180
antigens may be involved in the pathogenesis of the
skin lesions, it is hypothesized that new therapies
could involve the interruption of T- and B-cell activa-
tion upon exposure to BP180 peptides, thus rendering
the patient tolerant to this antigen.
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